Saniona AB has established a new research collaboration with Astronautx Ltd. in Alzheimer’s disease. The aim of the collaboration is to identify new treatments for Alzheimer’s disease and other neurodegenerative conditions by modulating a novel, undisclosed ion channel target. The research collaboration will use Saniona’s proprietary platform, Ionbase, for the modulation of ion channels.
Scribe Therapeutics Inc. has announced an expanded collaboration with Sanofi SA, under which Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including for sickle cell disease.
Genequantum Healthcare Co. Ltd. and Inxmed Co. Ltd. have signed a collaboration agreement under which Genequantum has granted nonexclusive licensing of its proprietary conjugation technology to Inxmed, supporting the development of the next generation of targeted antibody-drug conjugates (ADCs).
Eleven Therapeutics Ltd. has established a research collaboration with Novo Nordisk A/S for the identification of novel molecules that promote precise delivery of nucleic acid for cardiometabolic diseases by leveraging Eleven’s innovative Deliveri platform.
Cumulus Oncology Ltd. and Leadxpro AG have signed a research collaboration focused on the discovery and development of small molecules targeting an undisclosed and novel cancer-focused G protein-coupled receptor (GPCR).
Raya Therapeutic Inc. has entered into an early-stage R&D collaboration with Argenx SE to evaluate combinations of Raya’s pipeline of targeted small molecules with a potentially complementary product from Argenx.
A new academic and commercial collaboration between The Institute of Cancer Research, the Bellvitge Biomedical Research Institute (Institut d’Investigació Biomèdica de Bellvitge, IDIBELL) and Vivan Therapeutics (My Personal Therapeutics Ltd.) seeks to create cancer drugs less prone to drug resistance, with a particular focus on drugs that could target KRAS.
Altamira Therapeutics Ltd. has entered into a collaboration and option agreement with Heqet Therapeutics srl, a spin-out from King’s College London, to utilize the company’s proprietary Oligophore delivery platform in cardiovascular research.
The U.S. Department of Defense (DOD) has awarded Evotec SE’s subsidiary Just-Evotec Biologics Inc. a contract valued up to US$74 million for the rapid development of monoclonal antibody (MAb)-based drug product prototypes targeting orthopoxviruses.
RSS
